PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for October 18, 2005 Subscribe to this News Feed    
 

Relora® Significantly Reduces Stress, Anxiety and Sleep Latency - New Findings Presented at WorldNutra

Good news for people who suffer from anxiety. Next Pharmaceuticals has released the findings of a new study of their proprietary botanical ingredient, Relora, revealing that it reduces anxiety significantly. This news comes at a time when anxiety is extremely high among Americans.

Irvine, CA (PRWEB) October 18, 2005 -- Revealing the results of a new study, Next Pharmaceuticals announced today that their proprietary botanical ingredient Relora® (which is a blend of Magnolia officinalis and Phellodendron amurense extracts) significantly reduces anxiety, stress and sleep latency in women who suffer from these problems.

The new findings were presented at the upcoming WorldNutra Conference, Crown Plaza Anaheim Resort in Anaheim, California.

“The news headlines are ominous and Americans are worrying more than ever. Anxiety levels are up and the risk for overeating, heart disease and other disorders related to excessive stress has never been greater,” said Bob Garrison, President and CEO of Next Pharmaceuticals, Inc. “There is extensive research on Relora that indicates it can play a very useful role in helping people deal with daily anxiety issues.”

The Relora randomized, placebo-controlled, parallel-group, clinical trial was conducted to assess the safety and efficacy of the formulation in reducing anxiety, salivary cortisol and food intake. The study enrolled 40 healthy, overweight, physically active, 25-50 year old women with anxiety who reported eating more in response to stressful situations. Subjects were randomized (1:1) to receive either placebo or 750 mg of Relora for 6 weeks. An intent-to-treat analysis indicated that the Spielberger Trait Total and Anxiety Index scores improved significantly, and by twice as much with Relora as with placebo (p=0.047). The Relora group also had twice as much average reduction in sleep latency (11 minutes, p=0.012) as the placebo group (5 minutes, p=0.147). Most importantly, the formulation was found to significantly reduce anxiety and stress.

“Up until now, there was no natural formulation that has shown such results in reducing anxiety,” added Garrison. “People who have used Relora, appreciate it as an effective formula that helps them deal with the increasing tension in their lives.”

Next Pharmaceuticals, Inc. is a research and development company that markets its patented or patent-pending ingredients such as Relora®, Nexrutine®, Seditol® and Citri-Z™ to food, beverage, and dietary supplement companies seeking differentiation and a marketing edge with their healthy living products.
                    

 
  • # #

Technorati Tags

Bookmark -  Del.icio.us | Furl It | Technorati | Ask | MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION
Constance St. John
THE ST. JOHN GROUP
415-454-2243
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.